Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | MMP16 | P51512 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26454708 | 0.83 | TP53 (0.38) | ADAMTS4TP53SLC7A5 | |
| SCHEMBL14890392 | 0.78 | TP53 (0.40) | ADAMTS4TP53SLC7A5GABRR1MMP2 | |
| SCHEMBL15023 | 0.78 | TP53 (0.40) | ADAMTS4TP53SLC7A5GABRR1MMP2 | |
| SCHEMBL214942 | 0.78 | TP53 (0.40) | ADAMTS4TP53SLC7A5GABRR1MMP2 | |
| SCHEMBL18921013 | 0.78 | TP53 (0.40) | ADAMTS4TP53SLC7A5GABRR1MMP2 | |
| SCHEMBL4300140 | 0.76 | SLC7A5 (0.43) | ADAMTS4TP53SLC7A5GABRR1MMP2 | |
| SCHEMBL10654070 | 0.76 | SLC7A5 (0.43) | ADAMTS4TP53SLC7A5GABRR1MMP2 | |
| SCHEMBL17951879 | 0.74 | ADAMTS4 (0.37) | ADAMTS4TP53SLC7A5GABRR1MMP2 | |
| SCHEMBL20488172 | 0.74 | ADAMTS4 (0.37) | ADAMTS4TP53SLC7A5GABRR1MMP2 | |
| SCHEMBL8078677 | 0.74 | ADAMTS4 (0.41) | ADAMTS4TP53SLC7A5GABRR1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384121-B2 | Creation of peptide-based anti-tumor agent | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-07-12 | — | — | US | disclosed |
| US-20210017232-A1 | CREATION OF PEPTIDE-BASED ANTI-TUMOR AGENT | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017232-A1 | CREATION OF PEPTIDE-BASED ANTI-TUMOR AGENT | NGLY1, VIP, ETF1 | ADAMTS4 914/4885TP53 178/4885SLC7A5 794/4885 |
| US-11384121-B2 | Creation of peptide-based anti-tumor agent | NGLY1, VIP, ETF1 | ADAMTS4 914/4885TP53 178/4885SLC7A5 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.